EyePoint (EYPT) Research & Development (2010 - 2026)
EyePoint (EYPT) reported Research & Development of $72.1 million for Q1 2026, up 206037.14% on a YoY basis from N/an in Q1 2025, and up 144.61% sequentially from -$161.7 million in Q4 2025.
EyePoint (EYPT) Research & Development (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Research & Development data on file, last reported at $72.1 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 206037.14% year-over-year to $72.1 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (down 92.89% YoY), and the FY2025 full-year result was $90000.0, down 99.93% from the prior year.
- Research & Development grew to $72.1 million in Q1 2026, from -$161.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $132.8 million in Q4 2024 to a low of -$161.7 million in Q4 2025.
- A 5-year average of $16.5 million and a median of $15.7 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development sank 692.09% in 2023 and soared 206037.14% in 2026, its largest moves.
- Tracing EYPT's Research & Development over 5 years: stood at $5.9 million in 2022, then slumped by 692.09% to -$35.0 million in 2023, then surged by 479.32% to $132.8 million in 2024, then plunged by 221.75% to -$161.7 million in 2025, then soared by 144.61% to $72.1 million in 2026.
- Business Quant data shows EYPT's Research & Development at $72.1 million in Q1 2026, -$161.7 million in Q4 2025, and $47.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | 72.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.15 Mn |
| Dec 31, 2025 | -161.74 Mn |
| Sep 30, 2025 | 47.75 Mn |
| Jun 30, 2025 | 55.50 Mn |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 132.85 Mn |
| Sep 30, 2024 | 29.54 Mn |
| Jun 30, 2024 | 29.82 Mn |
| Mar 31, 2024 | 30.14 Mn |
| Dec 31, 2023 | -35.02 Mn |
| Sep 30, 2023 | 17.36 Mn |
| Jun 30, 2023 | 15.73 Mn |
| Mar 31, 2023 | 5.74 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | 11.16 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 9.95 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 8.50 Mn |
| Jun 30, 2021 | 5.61 Mn |